SIMLANDI

GrowthmAb

adalimumab-ryvk

BLAINJECTIONINJECTABLE

Approved

Feb 2024

Lifecycle

Growth

Competitive Pressure

30/100

Company

LUXEMBOURG, Luxembourg

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers